Pharmacoinformatics

1. The Structural Genomics
Consortium
PRESENTED BY –
SAROJ KUNDAN BHARTI
PHD 1ST YEAR (PHARMACY PRACTICE)
NIPER MOHALI

2. SGC IN NUTSHELL
• The Structural Genomics Consortium (SGC) is an international public-private
partnership incorporated as a not-for-profit organization in July 2004
• The SGC promotes the development of new medicines through open access research on
less studied areas of Human biology and Pathology.
• It’s core mandate is to determine the 3D structures targeting human proteins of
biomedical importance and proteins from human parasites that represent potential drug
targets.
• The SGC is led by Aled Edwards at the University of Toronto with additional activities at
Oxford University.

3. • The first two phases of the project has delivered over and above its initial goals.
• Phase III of the SGC began July 1, 2011 which ends on June 2015 & currently is
in phase four.
• A total of $61 million has been committed by funding partners, of which $28
million is from the public sector (including $2.5 million for one year from
Genome Canada) and $33 million from the private sector, including GSK, Pfizer,
Novartis, Lilly, Life Technologies, Abbott Laboratories and Takeda
Pharmaceuticals, with at least two new companies requesting membership.

4. • It works in collaboration with very extensive network of experts and collaborators.
• To date the SGC has been responsible for more than 25% of global output of new
human protein structures and more than 50% of the global output of protein
structures from human parasites.

5. SGC has three distinguishing features:
1. It releases outputs to the public domain without IP restriction on use until later stages of
clinical trials.
2. It has a distinctive way of engaging public and private actors and organizing research
activity. For a certain level of investment, a funding organization gains the rights to
influence the direction of research to a degree: for example, it can nominate targets to a
target list for researching; nominate a member to the scientific community and board of
directors of the SGC; and place scientists to work within the SGC laboratories.
3. It represents a large-scale, long-term, and multiple-funder initiative which has provided
stability to the field.

6. The SGC as a platform for knowledge
• Focus on three, interrelated yet conceptually distinct spheres of knowledge which emerge
from the SGC’s efforts:
1. The SGC as a model for investing in knowledge - what the motivations and rationale
for investing in the SGC are from the perspective of those who are engaged in it,
including funders, SGC researchers and external collaborators/stakeholders.
2. The SGC as a model for generating knowledge - perceived strengths and weaknesses
of the SGC model as it operates in practice.
3. The SGC as a model for extracting value from knowledge - value comes from both
the investment and generation of knowledge.

7. The SGC has also evolved across its three funding phases.
PHASE OF THE SGC OVERVIEW
Phase1
• In this phase primary objective was to determine the 3-D structures of 350 human
proteins and release them into the public domain via public databases.
Phase 2
• In Phase II the SGC planned to dedicate 80% of its effort to produce ~660
structures from proteins on the SGC target list, and 20% to determining three
human integral membrane proteins.
• These numbers would have risen to 1070 respectively if full funding had been
received.
Phase 3
• Phase III proposed 40% of resources should maintain the critical mass necessary
for the protein science based platform to support the structural genomics
programme and create the foundations for add on activities.
• Approx. 25% of resource should provide minimum support for the parasitology,
chemical probes and biological probes programs.
• 35% was unallocated and open for funder prioritization.

8. POSITION OF SGC IN DEVELOPING DRUG TARGET

9. SCG FLOW CHART FOR DOCUMENT AND DISSEMINATE DATA